INVESTOR ALERT: Investigation of Nektar Therapeutics Announced by Holzer & Holzer
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Business Wire
ATLANTA--(BUSINESS WIRE)-- Holzer & Holzer, LLC is investigating whether Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) complied with the federal securities laws. On October 1, 2018, Plainview LLC published a report raising questions about Nektar’s claims concerning its clinical stage drug, NKTR-214, and its ability to effectively treat cancer. The price of Nektar common stock fell significantly following these reports. If you purchased Nektar common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at cholzer@holzerlaw.com or Marshall P. Dees, Esq. at mdees@holzerlaw.com, or call the firm by toll-free telephone at (888) 508-6832. Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivativ
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at Jefferies Financial Group Inc. from $0.50 to $1.00. They now have a "hold" rating on the stock.MarketBeat
- Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 3/19/24 - Form D
- 3/15/24 - Form SC
- 3/14/24 - Form 3
- NKTR's page on the SEC website